<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115996</url>
  </required_header>
  <id_info>
    <org_study_id>R3918-HV-1659</org_study_id>
    <secondary_id>2016-004208-70</secondary_id>
    <nct_id>NCT03115996</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously and Subcutaneously Administered Human Monoclonal Antibody REGN3918 in Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous
      (SC) doses and a multiple dose regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to single IV or SC or multiple dose treatment with REGN3918
      or matched placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of TEAEs</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN3918; single dose IV and SC</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed via serum concentrations of REGN3918 over time; Area under the Curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of REGN3918; single dose IV and repeated SC doses</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed via serum concentrations of REGN3918 over time; peak concentration Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics profile of REGN3918</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed by CH50 assay over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic exploratory analysis</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Peak concentration Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of REGN3918</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <description>Assessed by measurement of anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>REGN3918 (Cohorts 1-4 &amp; 6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1-4 and 6a will receive sequential ascending doses of REGN3918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohorts 1-4 &amp; 6a)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts 1-4 and 6a will receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN3918 (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 and 6b will receive multiple doses of REGN3918</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 5 and 6b will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN3918</intervention_name>
    <description>Intravenous (IV) or Subcutaneous (SC)</description>
    <arm_group_label>REGN3918 (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_label>REGN3918 (Cohorts 1-4 &amp; 6a)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo (Cohort 5 &amp; 6b)</arm_group_label>
    <arm_group_label>Placebo (Cohorts 1-4 &amp; 6a)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

        A subject must meet the follow criteria to be eligible for inclusion in the study:

          1. Males and females from 18 to 50 years of age.

          2. Subject is judged to be in good health based on medical history, physical examination,
             vital sign measurements and laboratory safety tests performed at screening and/or
             prior to administration of initial dose of study drug

          3. The subject has a body mass index less than 30 kg/m2

          4. Willingness to undergo vaccination and antibiotic prophylaxis against N. meningitides.

        Key Exclusion Criteria:

        A subject who meets any of the following criteria will be excluded from the study:

          1. Any clinically significant physical examination abnormalities observed during the
             screening visit.

          2. Hospitalization for any reason within 30 days of the screening visit

          3. Persistent chronic or active recurring infection requiring treatment with antibiotics,
             antivirals, or antifungals.

          4. Subject has a history of meningococcal infection.

          5. Carriers of Neisseria meningitides based on cultures from naso-pharyngeal swabs during
             screening.

          6. Subject has had a splenectomy.

          7. Known allergy to penicillin class antibiotics

          8. Known or suspected complement deficiency, or abnormal complement C3, C4 or CH50 during
             screening.

          9. Recent (within the previous 2 months) bacterial, protozoal, viral or parasite
             infection requiring systemic treatment.

         10. History of tuberculosis or systemic fungal diseases

         11. HIV infection or HIV seropositivity at the screening visit

         12. Positive HBsAg, HBcAb, or hepatitis C antibody at the screening visit

         13. History of malignancy (except non-melanoma skin cancer or cervical in-situ)

         14. Pregnant or breastfeeding women

         15. Women of childbearing potential and men who are unwilling to practice highly effective
             contraception prior to the initial dose/start of the first treatment, during the
             study, and for at least 6 months after the last dose

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

